Knudsen et al. (20) derived a gene expression–based RB-pathway activity signature in RB1-deleted isogenic breast cancer cell lines exposed to CDK4/6 inhibitors, thereby modulating RB phosphorylation and resulting in inactivation of RB1. The gene discussed is CDK4; the disease is breast carcinoma.